Jiangsu Hengrui Pharmaceuticals Co.,Ltd is a major player in the Healthcare sector, specifically within the Drug Manufacturers industry. With a substantial market capitalization of 303.39 Billion CNY, it stands as a significant entity in its field. The stock has shown considerable short-term volatility, with a 7-day gain of 7.15% contrasting with a minor 24-hour dip of -0.70% to its current price of CNY45.72.

Based on our technical scoring system, Jiangsu Hengrui Pharmaceuticals receives a "Sell" rating with a total score of -3 out of +6. The primary driver for this bearish outlook is the strong long-term downtrend. The current price is significantly below its 200-day Simple Moving Average (CNY54.33), contributing a heavily weighted -4 points to the score. This downtrend is confirmed to be strong by the ADX indicator, which at 40.31 signals a powerful trend, with the DMI- prevailing over the DMI+. In contrast, there are some short-term bullish signals: the MACD histogram is positive, indicating upward momentum, and the On-Balance Volume (OBV) is above its moving average, suggesting recent accumulation. The RSI remains neutral at 46.38, not signaling overbought or oversold conditions.

In conclusion, the technical "Sell" rating is dominated by a powerful, established downtrend that outweighs recent positive short-term signals. From a fundamental perspective, the P/E ratio of 39.40 appears elevated, which could suggest the stock is priced optimistically relative to its earnings, aligning with a more cautious stance. The provided dividend yield is notably high at 38.0. While attractive, investors should verify its sustainability. With no recent earnings per share (EPS) data or upcoming earnings dates available, there is a lack of fundamental catalysts to challenge the prevailing negative technical picture.